biosimilars

Will new biosimilars hurt blockbuster autoimmune drug?New biosimilars may harm the sales of this autoimmune blockbuster.
Biosimilars Market Taking Off in the United StatesAfter many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
Pharmacists: Key Players as Biosimilars Enter the MarketPharmacists will have a central role in educating about biosimilar drugs.
Biosimilars Come  to Community Pharmacy
Biosimilars Come to Community PharmacyBiosimilars are now being dispensed from community pharmacies.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
Biosimilar familiarity expandsDermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.
Supreme Court Ruling Raises Biosimilars’ AccessHigh court ruling should make biosimilars available faster.
Samsung Gets First U.S. ApprovalThe second Remicade biosimilar is only the fifth biosimilar approved in the United States.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.